Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LANTUS

« Back to Dashboard

Summary for Tradename: LANTUS

Patents:8
Applicants:1
NDAs:1
Suppliers: see list5
2013 Sales:$2,556,825,000

Pharmacology for Tradename: LANTUS

Ingredient-typeInsulin
Drug ClassInsulin Analog

Clinical Trials for: LANTUS

Insulin Glargine "All to Target" Trial
Status: Completed Condition: Diabetes Mellitus, Type 2

Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin
Status: Completed Condition: Hyperglycemia; Diabetes

Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes
Status: Not yet recruiting Condition: Type 1 Diabetes; Hypoglycemia

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes
Status: Completed Condition: Type 2 Diabetes Mellitus

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Status: Recruiting Condition: Type 2 Diabetes; Renal Insufficiency

A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus
Status: Completed Condition: Diabetes Mellitus, Type 1

A Study of LY2963016 in Healthy Participants
Status: Completed Condition: Healthy Volunteers

A Study to Compare LY2963016 and US-approved LantusĀ® After Single Dose Administration to Healthy Participants
Status: Completed Condition: Healthy

Perioperative Insulin Glargine Dosing Study
Status: Completed Condition: Diabetes; Surgery

Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus
Status: Completed Condition: Diabetes Mellitus, Type 2

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
LANTUS
insulin glargine recombinant
INJECTABLE;INJECTION021081Apr 20, 2000RXYes5,656,722*PED<disabled>Y<disabled>
Sanofi Aventis Us
LANTUS
insulin glargine recombinant
INJECTABLE;INJECTION021081Apr 20, 2000RXYes7,918,833*PED<disabled>Y<disabled>
Sanofi Aventis Us
LANTUS SOLOSTAR
insulin glargine recombinant
INJECTABLE;INJECTION021081Apr 27, 2007RXYes8,603,044<disabled>Y<disabled>
Sanofi Aventis Us
LANTUS SOLOSTAR
insulin glargine recombinant
INJECTABLE;INJECTION021081Apr 27, 2007RXYes8,556,864<disabled>Y<disabled>
Sanofi Aventis Us
LANTUS SOLOSTAR
insulin glargine recombinant
INJECTABLE;INJECTION021081Apr 27, 2007RXYes8,679,069<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc